22nd Jan 2026 DESTINY-Gastric02 findings on trastuzumab deruxtecan in HER2-positive gastric cancer: plain language summary
11th Apr 2023 Plain Language Summary: the CheckMate 649 study compares nivolumab in combination with chemotherapy with chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
